Newcells Biotech and Takeda Pharmaceutical International Co. have collaborated in a study designed to assess drug safety. The study evaluated a set of 36 known drugs and…
Read update 23rd February, 2021Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25m worth of funding to accelerate their growth plans in the international life sciences market.The funding…
Read update 26th June, 2020Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory
Read update 18th March, 2020As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in…
Read update 16th December, 2019Newcells Biotech are excited to announce that they are Phase II contract winners of the NC3Rs-funded CRACK IT Challenge (named ImmuLiver). They have been awarded a further funding to…
Read update 22nd October, 2019Newcells Biotech is pleased to announce the acquisition of intellectual property pertaining to the methodology for the differentiation of three-dimensional retinal org
Read update 18th July, 2019Newcells Biotech is pleased to announce that it has appointed Dr Frank Armstrong to its Board as a Non-executive Director. “Attracting an executive of Frank’s proven track-record and…
Read update 24th April, 2019Newcells Biotech are one…
Read update 20th December, 20182018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team. Here are some of…
Read update 9th November, 2018Congress Round-Up The International Congress on In Vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018. This year marks its 20th meeting, with the general theme of new…
Read update 13th September, 2018Newcells Biotech has announced that Dr Colin Brown, one of the world’s leading experts on drug transport and drug toxicity in kidney will join the company as Director of ADMET Technology….
Read update 11th July, 2018The meeting brings together individuals who are working on drug/xenobiotic research across a diverse range of fields such as clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal…
Read update